Panelists discuss how clinical and patient-specific factors, such as comorbidities, age, and risk profiles, influence the selection of Bruton tyrosine kinase (BTK) inhibitors for treatment-naive ...

So I think that actually, to be honest, could be an entire session all by itself, because lots of ways in which BTK inhibitors are impacting treatment. I would say my summary, if I was to say ...

BTK inhibitors, including the commonly used drug ibrutinib, block B cells' signaling pathway. This is helpful for treating B-cell lymphomas because the cancers arise when this signaling pathway ...

And what I mean by that is BTK inhibitors have really shown significant benefit, particularly when combined with therapies or used in maintenance thereafter. And that has really put the whole ...